Tissue Collection for ER and Her2 Diagnoses for Patients with Metastatic Breast Cancer (8085)
Quantification of ER and Her2 in Bone Biopsy using a Multiple-Immuno-MRM assay in Metastatic Breast Cancer
||Metastatic Breast Cancer
This is a clinical trial designed for SCCA stage 4 (metastatic) breast cancer patients scheduled (or anticipated to be scheduled) for an image-guided bone biopsy (to be done at HMC) as part of their standard of care. Patients can be referred by their physician for this no extra visits, no extra procedures trial. This study requires an additional collection of tissue, done simultaneously with the original biopsy pull, in the same pull site. The additional tissue will only be used if it is not needed for the patient’s diagnosis. FFPE tissue block from primary diagnosis will be obtained for central analysis when possible. There is no participant remuneration for this trial. This trial is a great option for patients who want to greatly contribute to research with exerting little to no effort.
Seattle Cancer Care Alliance
Eligibility Criteria (must meet the following to participate in this study)
- Metastatic Breast Cancer, Stage 4
- Patient must be scheduled or have orders to be scheduled for an image-guided bone biopsy
October 20, 2014
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.